JP2005505247A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505247A5 JP2005505247A5 JP2002578401A JP2002578401A JP2005505247A5 JP 2005505247 A5 JP2005505247 A5 JP 2005505247A5 JP 2002578401 A JP2002578401 A JP 2002578401A JP 2002578401 A JP2002578401 A JP 2002578401A JP 2005505247 A5 JP2005505247 A5 JP 2005505247A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- amino acid
- group
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 229920001184 polypeptide Polymers 0.000 claims description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 230000003902 lesion Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000003334 potential effect Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims 33
- 108020004707 nucleic acids Proteins 0.000 claims 28
- 102000039446 nucleic acids Human genes 0.000 claims 28
- 239000002773 nucleotide Substances 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 239000000523 sample Substances 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229940124606 potential therapeutic agent Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (46)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27419401P | 2001-03-08 | 2001-03-08 | |
| US27432201P | 2001-03-08 | 2001-03-08 | |
| US27428101P | 2001-03-08 | 2001-03-08 | |
| US27484901P | 2001-03-09 | 2001-03-09 | |
| US27560101P | 2001-03-13 | 2001-03-13 | |
| US27557801P | 2001-03-13 | 2001-03-13 | |
| US27557901P | 2001-03-13 | 2001-03-13 | |
| US27600001P | 2001-03-14 | 2001-03-14 | |
| US27677601P | 2001-03-16 | 2001-03-16 | |
| US27699401P | 2001-03-19 | 2001-03-19 | |
| US27733801P | 2001-03-20 | 2001-03-20 | |
| US27723901P | 2001-03-20 | 2001-03-20 | |
| US27732701P | 2001-03-20 | 2001-03-20 | |
| US27779101P | 2001-03-21 | 2001-03-21 | |
| US27783301P | 2001-03-22 | 2001-03-22 | |
| US27815201P | 2001-03-23 | 2001-03-23 | |
| US27889401P | 2001-03-26 | 2001-03-26 | |
| US27899901P | 2001-03-27 | 2001-03-27 | |
| US27903601P | 2001-03-27 | 2001-03-27 | |
| US28023301P | 2001-03-30 | 2001-03-30 | |
| US28080201P | 2001-04-02 | 2001-04-02 | |
| US28805201P | 2001-05-02 | 2001-05-02 | |
| US28806601P | 2001-05-02 | 2001-05-02 | |
| US28822801P | 2001-05-02 | 2001-05-02 | |
| US29176601P | 2001-05-17 | 2001-05-17 | |
| US29669301P | 2001-06-07 | 2001-06-07 | |
| US29685601P | 2001-06-08 | 2001-06-08 | |
| US30323701P | 2001-07-05 | 2001-07-05 | |
| US30323001P | 2001-07-05 | 2001-07-05 | |
| US31091301P | 2001-08-08 | 2001-08-08 | |
| US31197801P | 2001-08-13 | 2001-08-13 | |
| US31219101P | 2001-08-14 | 2001-08-14 | |
| US31291601P | 2001-08-16 | 2001-08-16 | |
| US31318201P | 2001-08-17 | 2001-08-17 | |
| US31362601P | 2001-08-20 | 2001-08-20 | |
| US31401801P | 2001-08-21 | 2001-08-21 | |
| US31522701P | 2001-08-27 | 2001-08-27 | |
| US31840301P | 2001-09-10 | 2001-09-10 | |
| US31851001P | 2001-09-10 | 2001-09-10 | |
| US32236001P | 2001-09-14 | 2001-09-14 | |
| US32229601P | 2001-09-14 | 2001-09-14 | |
| US32537801P | 2001-09-27 | 2001-09-27 | |
| US34539901P | 2001-11-09 | 2001-11-09 | |
| US33248601P | 2001-11-09 | 2001-11-09 | |
| US10/094,886 US20040002120A1 (en) | 2001-03-08 | 2002-03-07 | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| PCT/US2002/007355 WO2002079398A2 (en) | 2001-03-08 | 2002-03-08 | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505247A JP2005505247A (ja) | 2005-02-24 |
| JP2005505247A5 true JP2005505247A5 (enExample) | 2006-01-05 |
Family
ID=29274020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002578401A Pending JP2005505247A (ja) | 2001-03-08 | 2002-03-08 | 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2005505247A (enExample) |
| CA (1) | CA2440108A1 (enExample) |
-
2002
- 2002-03-08 JP JP2002578401A patent/JP2005505247A/ja active Pending
- 2002-03-08 CA CA002440108A patent/CA2440108A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505075A5 (enExample) | ||
| JP2005512515A5 (enExample) | ||
| JP2019056013A (ja) | ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療 | |
| BR122016021558A2 (pt) | Polipeptídeos isolados, seus usos, e composição farmacêutica | |
| JP2000093186A (ja) | Ｆｒｉｚｚｌｅｄ―４ポリペプチドおよびＦｒｉｚｚｌｅｄ―４ポリヌクレオチド | |
| WO2018195390A1 (en) | Methods of treating gastrointestinal motility -related disorders using variants and fusions of fgf19/fgf21 polypeptides | |
| BR112021013874A2 (pt) | Composição de ácido nucleico, vetor de terapia de gene de mamífero, partícula de vírus adeno-associado, métodos para tratar hemofilia a e para produzir uma partícula de vírus adeno-associado, e, uso de uma composição de ácido nucleico e de um vetor de terapia de gene de mamífero | |
| JP2002281985A (ja) | Ｍｂｇｐ１ポリペプチドおよびポリヌクレオチド | |
| JPH1175873A (ja) | 新規化合物 | |
| ES2582559T3 (es) | Factor trófico para el tratamiento de las enfermedades degenerativas de la retina | |
| JP2004533235A5 (enExample) | ||
| JP2005528080A5 (enExample) | ||
| JPH1118786A (ja) | 腫瘍壊死関連受容体ｔｒ７ | |
| JPH1142092A (ja) | ヒト心臓／脳トロイド様タンパク質 | |
| JP2005506833A5 (enExample) | ||
| JP2005505247A5 (enExample) | ||
| JPH1175874A (ja) | 新規化合物 | |
| JPH1198989A (ja) | 新規化合物 | |
| JP2005507236A5 (enExample) | ||
| JP2000512506A (ja) | 新規化合物 | |
| WO2002030974A2 (en) | Proteins and nucleic acids encoding same | |
| JP2004512310A (ja) | 新規用途 | |
| JP2005504514A5 (enExample) | ||
| JP2002507413A (ja) | サイトカインファミリーのメンバー，２−２１ | |
| JP2005508604A5 (enExample) |